Clinical trial of camrelizumab combined with apatinib in the treatment of elderly patients with intermediate and advanced primary liver cancer
10.13699/j.cnki.1001-6821.2024.23.004
- VernacularTitle:卡瑞利珠单抗联合阿帕替尼治疗老年中晚期原发性肝癌患者的临床研究
- Author:
Xiao REN
1
;
Hong-li WANG
1
;
Yun-he LIU
1
;
Ling SHEN
1
;
Yao-sheng ZHANG
1
Author Information
1. 南阳医学高等专科学校第一附属医院肿瘤内科三病区,河南南阳 473000
- Publication Type:Journal Article
- Keywords:
camrelizumab injection;
apatinib tablet;
primary liver cancer;
intermediate and advanced;
elderly;
cellular immune function;
prognosis
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(23):3385-3389
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe clinical effect and safety of camrelizumab(Cam)injection combined with apatinib(Apa)tablets in the treatment of elderly patients with intermediate and advanced primary liver cancer(PLC).Methods According to cohort method,elderly patients with intermediate and advanced PLC were divided into treatment group and control group.The control group was given oral Apa(250 mg,once/d),while treatment group was given intravenous drip of Cam for injection(200 mg)on the first day on basis of control group.All patients were treated for 2 courses(3 weeks/course).The clinical curative effect,liver function indexes,cellular immune function indexes,tumor markers and prognosis in the two groups were compared,and safety was evaluated.Results There were 46 cases in control group and 52 cases in treatment group.After treatment,disease control rates in treatment group and the control group were 80.77％(42 cases/52 cases)and 60.87％(28 cases/46 cases),objective remission rates were 59.62％(31 cases/52 cases)and 39.13％(18 cases/46 cases),and the differences were statistically significant(all P＜0.05).After treatment,levels of total bilirubin(TBil)in treatment group and control group were(19.65±3.04)and(24.98±3.76)μmol·L-1,levels of glutamic oxalacetic transaminase(GOT)were(38.21±3.74)and(47.68±4.51)U·L-1,levels of glutamic pyruvic transaminase(GPT)were(42.63±4.08)and(53.71±4.73)U·L-1,levels of alpha-fetoprotein(AFP)were(121.43±23.29)and(195.62±30.43)ng·mL-1,levels of carbohydrate antigen(CA)199 were(34.03±4.39)and(47.53±4.65)ng·mL-1,levels of carcinoembryonic antigen(CEA)were(17.05±2.67)and(26.49±3.52)ng·mL-1,6-month progression-free survival rates were 59.62％(31 cases/52 cases)and 32.61％(15 cases/46 cases),progression-free survival were(5.33±0.89)and(4.75±0.98)months,and the differences were statistically significant(all P＜0.05).The adverse drug reactions in the two groups were mainly on proteinuria,elevation of blood pressure,hand-foot syndrome,hypothyroidism,fatigue and leukopenia.There was no significant difference in total incidences of adverse drug reactions between treatment group and control group[71.16％(37 cases/52 cases)vs 54.35％(25 cases/46 cases),P＞0.05].Conclusion Cam injection combined with Apa tablets can promote the recovery of liver function,regulate levels of tumor markers,improve cellular immune function and prognosis in elderly patients with intermediate and advanced PLC.
